Agilent Technologies, Inc. A
We take great care to ensure that the data presented and summarized in this overview for AGILENT TECHNOLOGIES, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding A
View all-
Vanguard Group Inc Valley Forge, PA33.2MShares$4.05 Billion0.08% of portfolio
-
Black Rock Inc. New York, NY25.3MShares$3.09 Billion0.08% of portfolio
-
State Street Corp Boston, MA12.7MShares$1.55 Billion0.07% of portfolio
-
Massachusetts Financial Services CO Boston, MA12.4MShares$1.52 Billion0.56% of portfolio
-
Wellington Management Group LLP Boston, MA9.31MShares$1.14 Billion0.24% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.23MShares$1.01 Billion0.68% of portfolio
-
Geode Capital Management, LLC Boston, MA7MShares$856 Million0.07% of portfolio
-
Pictet Asset Management Sa Geneva 73, V86.64MShares$812 Million0.96% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V85.21MShares$637 Million0.79% of portfolio
-
Morgan Stanley New York, NY4.5MShares$550 Million0.04% of portfolio
Latest Institutional Activity in A
Top Purchases
Top Sells
About A
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Insider Transactions at A
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 17
2025
|
Rodney Gonsalves V.P., Corporate Controller |
SELL
Open market or private sale
|
Direct |
1,907
-8.05%
|
$230,747
$121.98 P/Share
|
Mar 14
2025
|
Boon Hwee Koh Director |
SELL
Payment of exercise price or tax liability
|
Direct |
546
-0.88%
|
$66,066
$121.18 P/Share
|
Mar 14
2025
|
Boon Hwee Koh Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,819
+2.85%
|
$220,099
$121.18 P/Share
|
Mar 14
2025
|
Mala Anand Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,819
+11.11%
|
$220,099
$121.18 P/Share
|
Mar 14
2025
|
Otis W Brawley Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,631
+11.26%
|
$318,351
$121.18 P/Share
|
Mar 14
2025
|
Mikael Dolsten Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,819
+19.42%
|
$220,099
$121.18 P/Share
|
Mar 14
2025
|
Heidi Fields Director |
BUY
Grant, award, or other acquisition
|
Indirect |
1,819
+3.0%
|
$220,099
$121.18 P/Share
|
Mar 14
2025
|
Daniel K Podolsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,819
+4.62%
|
$220,099
$121.18 P/Share
|
Mar 14
2025
|
Sue H. Rataj Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,819
+7.81%
|
$220,099
$121.18 P/Share
|
Mar 14
2025
|
George A Scangos Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,819
+8.15%
|
$220,099
$121.18 P/Share
|
Mar 14
2025
|
Dow R Wilson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,819
+9.15%
|
$220,099
$121.18 P/Share
|
Mar 06
2025
|
Sue H. Rataj Director |
SELL
Open market or private sale
|
Direct |
6,971
-26.2%
|
$878,346
$126.38 P/Share
|
Mar 05
2025
|
Robert W. Mc Mahon Sr. VP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
5,385
+3.03%
|
$678,510
$126.51 P/Share
|
Feb 28
2025
|
Angelica Riemann Senior Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
84
-0.44%
|
$10,668
$127.92 P/Share
|
Feb 28
2025
|
Padraig Mcdonnell President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
278
-0.7%
|
$35,306
$127.92 P/Share
|
Feb 28
2025
|
Jonah Prevost Kirkwood Senior Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
124
-1.49%
|
$15,748
$127.92 P/Share
|
Jan 28
2025
|
Rodney Gonsalves V.P., Corporate Controller |
BUY
Bona fide gift
|
Indirect |
7,148
+49.86%
|
$1,072,200
$150.34 P/Share
|
Jan 28
2025
|
Rodney Gonsalves V.P., Corporate Controller |
SELL
Bona fide gift
|
Direct |
7,148
-30.17%
|
$1,072,200
$150.34 P/Share
|
Jan 21
2025
|
Padraig Mcdonnell President and CEO |
SELL
Open market or private sale
|
Direct |
1,911
-4.6%
|
$286,650
$150.0 P/Share
|
Nov 29
2024
|
Henrik Ancher Jensen Sr Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,577
-2.84%
|
$353,049
$137.97 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 101K shares |
---|---|
Bona fide gift | 11.1K shares |
Payment of exercise price or tax liability | 22K shares |
---|---|
Open market or private sale | 51.5K shares |
Bona fide gift | 11.1K shares |